LONG PFE
Price retest support line
Potential entry $34.50 and below
Pfizer’s fourth-quarter results were mixed as it missed estimates for earnings while beating the same for sales. Pfizer’s financial outlook for 2021 was quite upbeat.
Potential entry $34.50 and below
Pfizer’s fourth-quarter results were mixed as it missed estimates for earnings while beating the same for sales. Pfizer’s financial outlook for 2021 was quite upbeat.
免責事項
これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。